Barrett & Company’s Galectin Therapeutics GALT Stock Holding History

Barrett & Company’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,834	Closed	-$16.2K	–	667
2025 Q3	$16.2K	Hold	3,834	–	–	0.01%	428
2025 Q2	$8.09K	Hold	3,834	–	–	﹤0.01%	494
2025 Q1	$4.68K	Hold	3,834	–	–	﹤0.01%	501
2024 Q4	$4.95K	Hold	3,834	–	–	﹤0.01%	494
2024 Q3	$10.5K	Hold	3,834	–	–	﹤0.01%	424
2024 Q2	$8.66K	Hold	3,834	–	–	﹤0.01%	438
2024 Q1	$9.16K	Hold	3,834	–	–	﹤0.01%	437
2023 Q4	$6.36K	Sell	3,834 -1,150	-23%	-$2.23K	﹤0.01%	452
2023 Q3	$9.57K	Hold	4,984	–	–	0.01%	422
2023 Q2	$7.18K	Hold	4,984	–	–	﹤0.01%	439
2023 Q1	$10.5K	Hold	4,984	–	–	0.01%	383
2022 Q4	$5.63K	Hold	4,984	–	–	﹤0.01%	436
2022 Q3	$5.63K	Buy	+4,984	New	+$9.31K	﹤0.01%	436

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barrett & Company's GALT Position: Q4 2025 in Review

Barrett & Company sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 3,834 shares — an estimated $16.2K sold.

Barrett & Company first reported a position in GALT in Q3 2022 and held it in 13 quarters. The position peaked at $16.2K in Q3 2025. 97 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

Barrett & Company reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
Barrett & Company sold 3,834 Galectin Therapeutics shares in Q4 2025, an estimated $16.2K.
Barrett & Company first reported a position in Galectin Therapeutics in Q3 2022 and held it in 13 quarters.
Barrett & Company's Galectin Therapeutics position peaked at $16.2K in Q3 2025.
97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Barrett & Company's 13F filing for Q4 2025, filed 28 Jan 2026.